Photo by Dimitri Karastelev on Unsplash
One Antibody Trial Is Halted, While Others Continue
An ongoing trial of the antibody bamlanivimab—administered with remdesivir, an antiviral medication—on hospitalized COVID-19 patients has been halted by bamlanivimab’s manufacturer Eli Lilly. The decision was made to stop the trial after evidence showed the therapy had little positive effect on those with serious COVID-19 illness. However, the pharmaceutical company is continuing trials on bamlanivimab in different settings, including evaluating its effect on patients in the earliest stages of COVID-19. Click here to read more.